An intravenous programmed death-1 inhibitor to treat advanced treatment-naive melanoma.
Horizon Scanning
It is a challenge for health plans and clinicians to know what emerging technologies are in the preapproval phase and what their clinical, financial, and risk impacts might be. This is where we come in.The Hayes Horizon Scanning Solution identifies innovative and potentially disruptive health technologies that are in various stages of the regulatory approval process. Our Research Analysts continually investigate new technologies that are on the horizon or in the early stages of clinical investigation, as well as the testing of existing technologies that may be seeking approval for new clinical applications. Hayes Horizon Scanning helps you track emerging technologies before you need to make decisions. Accessed through the Hayes Knowledge Center, Hayes Horizon Scanning addresses the following fundamental questions to help our clients forecast emerging technologies:
- Is this emerging technology new or replacing an existing technology?
- Where is this technology in the FDA regulatory process?
- When will this technology be commercially available in the market?
- What is the projected use, cost, and financial impact of this technology?
Odalasvir (ACH-3102), ACH-3422, and Sovaprevir (ACH-1625) All-Oral Regimens for Chronic HCV Infection
Investigational direct-acting antivirals for interferon-free combination regimens to treat hepatitis C virus infection.
Galeterone (TOK-001)
A multitargeted oral steroid analog to treat metastatic castration-resistant prostate cancer in patients whose tumors express the AR-V7 splice variant.
LY2951742 for Migraine Headache Prevention
A subcutaneously administered monoclonal antibody for prevention of frequent episodic migraine headache.
Entresto (Valsartan and Sacubitril) for Heart Failure
Entresto is a twice-daily valsartan and sacubitril combination pill to treat heart failure in patients with reduced ejection fraction. Entresto is also in development to treat heart failure in patients with preserved ejection fraction and to treat hypertension.
Orkambi (Kalydeco and Lumacaftor Combination Pill)
Orkambi is fixed-dose combination pill to treat cystic fibrosis in patients ≥ 12 years of age who are homozygous for the F508del mutation in the CFTR gene.
Lutonix 035 Drug-Coated Balloon (DCB) PTA Catheter
A drug-coated balloon PTA catheter to treat peripheral artery disease.
Afrezza (Insulin Human) Inhalation Powder
|
Manufacturer |
MannKind Corp. Sanofi has licensing agreement for global commercialization. |
||||
|
Hayes Viewpoint |
Afrezza is a rapid… Keytruda (Pembrolizumab) for Yervoy-Refractory Advanced Melanoma
|